8 Antiobesity Therapies to Watch Closely
Dual and triple incretin agonists continue to lead the new therapies in the antiobesity pipeline. Here is an at-a-glance update of their progress toward approval.
CagriSema Novo Nordisk. Ongoing phase 3 REDEFINE trials
Retatrutide - Lilly. Triple agonist targeting glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptors
Retatrutide - Lilly. Ongoing phase 3 TRIUMPH trials
Danuglipron - Pfizer. Oral tablet formulation of a GLP-1 receptor agonist
Danuglipron - Pfizer. Next steps: Ongoing open-label study supports once-daily candidate
Survodutide - Boehringer Ingelheim. Subcutaneous glucagon/GLP-1 receptor dual agonist
Survodutide - Boehringer Ingelheim. Ongoing SYNCHRONIZE phase 3 trials
GSBR-1290 - Structure Therapeutics. Oral small molecule GLP-1RA
Orforglipron - Lilly. Oral nonpeptide GLP-1RA
Orforglipron - Lilly. Ongoing ATTAIN and ACHIEVE phase 3 trials
MariTide - Amgen. Bispecific gastric inhibitory polypeptide receptor antagonist and GLP-1 receptor agonist
Monlunabant - Novo Nordisk. CB1 receptor inverse agonist; affects metabolism, appetite
As in our 5 Obesity Drugs Worth Watching: 2024-2025 slide show from about midyear, nearly all of the 8 in this pipeline lineup are investigational incretin analogues; several are dual receptor agonists and one is a triple agonist. Of promising news for many people, 3 are oral formulations that, if approved, offer treatment options for individuals who are uncomfortable with needles or with the autoinjector device.
The number of companies vying to deliver the next most effective molecule or combination of molecules that will modify the underlying pathology of obesity with negligible, or at least minimal, adverse effects increases by the day.
Topline data for most of the 8 agents highlighted in this slide show have been presented at professional society meetings over the past year and the companies behind them plan new readouts either late this year or in early-mid 2025. Information for the slide show was culled from an article on eMPR web site as well as from manufacturer news.
